Zum Inhalt springen

Nur-Lesen-Fassung: Das Forschungsinformationssystem (FIS) ist aus Sicherheitsgründen vorübergehend durch diese Nur-Lesen-Fassung ersetzt. Alle öffentlichen Inhalte und Volltexte sind weiterhin abrufbar; Anmeldung, Bearbeitung, Einreichung und Statistiken stehen nicht zur Verfügung. Bei Fragen: fis@uni-bamberg.de

Start › Publikationen › ACTonDiabetes : study protocol of a pragmatic randomised controlled trial for the evaluation of an acceptance and commitment-based internet-based and mobile-based intervention for adults living with type 1 or type 2 diabetes

Publikation

ACTonDiabetes : study protocol of a pragmatic randomised controlled trial for the evaluation of an acceptance and commitment-based internet-based and mobile-based intervention for adults living with type 1 or type 2 diabetes

Bendig, Eileen; Schmitt, Andreas; Wittenberg, Amelie; u. a. (2024): ACTonDiabetes : study protocol of a pragmatic randomised controlled trial for the evaluation of an acceptance and commitment-based internet-based and mobile-based intervention for adults living with type 1 or type 2 diabetes, in: Bamberg: Otto-Friedrich-Universität, S. 1–13.

Details

Fakultät/Lehrstuhl
Autorin(nen)/Autor(en)
Bendig, Eileen
Schmitt, Andreas
Wittenberg, Amelie
Moshagen, Morten
Baumeister, Harald
Verlagsangabe
Otto-Friedrich-Universität : Bamberg
Erscheinungsjahr
2024
Quelle/Weitere Ausgabe
BMJ open, 12 (2022), 9, e059336, S. 1-13. - ISSN: 2044-6055
Jahr der Erstpublikation
2022
Sprache(n)
Englisch
Lizenz
URN
Abstract

Introduction

Living with diabetes can be burdensome and lead to serious emotional distress and impaired mental health. Acceptance and commitment therapy (ACT) can support people facing the challenges of living with diabetes. This trial aims to evaluate the effectiveness and cost-effectiveness of the internet-based and mobile-based intervention (IMI) ‘ACTonDiabetes’ in reducing diabetes distress against enhanced treatment as usual (TAU+) following specialised diabetes care.

Methods and analysis

A two-armed pragmatic randomised controlled trial will be conducted to evaluate the guided IMI ACTonDiabetes against TAU+. A total of 210 adults with type 1 or type 2 diabetes and elevated diabetes distress (Problem Areas in Diabetes ≥40) will be recruited at a specialised diabetes centre. The intervention begins 2–4 weeks after hospital discharge and takes about 7–10 weeks to complete. Assessments are performed at baseline and 5 and 10 weeks as well as 6 and 12 months after randomisation. The primary outcome is diabetes distress at a 10-week follow-up (T2). Secondary outcomes are depression (Patient Health Questionnaire-8), psychological well-being (WHO-5), quality of life (Assessment of Quality of Life-8 Dimension), Diabetes-related Self-Management Questionnaire, diabetes acceptance (Acceptance and Action Diabetes Questionnaire) and negative treatment effects (Inventory for the Assessment of Negative Effects of Psychotherapy). All statistical analyses will be performed based on the intention-to-treat principle with additional per-protocol analyses. Changes in outcomes will be evaluated using the general linear model. A health-economic evaluation will be conducted from a societal perspective. Reasons for drop-out will be systematically investigated.

Ethics and dissemination

This clinical trial has been approved by the State Medical Chamber of Baden-Württemberg (file no. B-F-2019-010). Trial results will be submitted for publication in a peer-reviewed journal and presented at conferences.

Trial registration number DRKS00016738.

GND-Schlagwort(e)
Diabetes mellitus
Freie Schlagwort(e)
Diabetes
DDC-Klassifikation
150 Psychologie
RVK-Klassifikation
YC 7200
Peer Reviewed
ja
Internationale Verbreitung
ja
Open-Access-Zeitschrift
ja
Dokumenttyp
Artikel in einer Zeitschrift / Postprint
URI
Datum der Freischaltung
26.01.2024

Permalink: https://fis.uni-bamberg.de/handle/uniba/93098 · Daten als JSON · Zitieren: BibTeX · RIS

Datenstand: 15.11.2026

Eingeschränkter Lesezugriff: Anmeldung, Bearbeitung und Einreichung sind vorübergehend deaktiviert.